Thyrocare Technologies Limited (NSE:THYROCARE)
India
· Delayed Price · Currency is INR 692.40
-28.40 (-3.94%)
Apr 4, 2025, 3:29 PM IST
Thyrocare Technologies Revenue
Thyrocare Technologies had revenue of 1.66B INR in the quarter ending December 31, 2024, with 23.14% growth. This brings the company's revenue in the last twelve months to 6.54B, up 18.23% year-over-year. In the fiscal year ending March 31, 2024, Thyrocare Technologies had annual revenue of 5.72B with 8.58% growth.
Revenue (ttm)
6.54B
Revenue Growth
+18.23%
P/S Ratio
n/a
Revenue / Employee
3.87M
Employees
1,693
Market Cap
36.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 5.72B | 452.10M | 8.58% |
| Mar 31, 2023 | 5.27B | -621.90M | -10.56% |
| Mar 31, 2022 | 5.89B | 942.40M | 19.05% |
| Mar 31, 2021 | 4.95B | 603.60M | 13.90% |
| Mar 31, 2020 | 4.34B | 303.30M | 7.51% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Thyrocare Technologies News
- 2 months ago - Thyrocare Technologies Q3 FY25 Results: Revenue jumps 23.2% YoY to Rs 165.9 crore, Net Profit surges 24% YoY - Business Upturn